Originally Posted by forgot to bid

The World Health Organization and a number of national governments have changed their Covid-19 policies and treatments on the basis of flawed data from a little-known US healthcare analytics company, also calling into question the integrity of key studies published in some of the world’s most prestigious medical journals.

A Guardian investigation can reveal the US-based company Surgisphere, whose handful of employees appear to include a science fiction writer and an adult-content model, has provided data for multiple studies on Covid-19 co-authored by its chief executive, but has so far failed to adequately explain its data or methodology.

Data it claims to have legitimately obtained from more than a thousand hospitals worldwide formed the basis of scientific articles that have led to changes in Covid-19 treatment policies in Latin American countries. It was also behind a decision by the WHO and research institutes around the world to halt trials of the controversial drug hydroxychloroquine.

On Wednesday, the WHO announced those trials would now resume.

https://www.theguardian.com/world/20...oxychloroquine

Originally Posted by forgot to bid

The World Health Organization and a number of national governments have changed their Covid-19 policies and treatments on the basis of flawed data from a little-known US healthcare analytics company, also calling into question the integrity of key studies published in some of the world’s most prestigious medical journals.

A Guardian investigation can reveal the US-based company Surgisphere, whose handful of employees appear to include a science fiction writer and an adult-content model, has provided data for multiple studies on Covid-19 co-authored by its chief executive, but has so far failed to adequately explain its data or methodology.

Data it claims to have legitimately obtained from more than a thousand hospitals worldwide formed the basis of scientific articles that have led to changes in Covid-19 treatment policies in Latin American countries. It was also behind a decision by the WHO and research institutes around the world to halt trials of the controversial drug hydroxychloroquine.

On Wednesday, the WHO announced those trials would now resume.

https://www.theguardian.com/world/20...oxychloroquine

Originally Posted by All 5 Stages

Vegas Casinos are open for business ...

https://www.fox5vegas.com/coronaviru...5e85ca414.html

A5S

Originally Posted by Gspeed

Malaria drug touted by Trump fails to prevent COVID-19 in high profile study

https://www.reuters.com/article/us-h...-idUSKBN23A34F

Originally Posted by forgot to bid

kind of validates what the Guardian article said, they relied on a bad study to shut down or even damage the ongoing studies like in the Reuter’s article. That’s a shame. Good to see in that Reuter’s article that the University of Minnesota trial, 40% of the those who took hydroxychloroquine reported less serious side effects like nausea and abdominal discomfort versus 17% in the placebo group.

Originally Posted by Phins2right

Just got to dodge the rioters and Antifa on strip now.

Originally Posted by Gspeed

Originally Posted by forgot to bid

Both Lancet and New England Journal of Medicine have retracted their original studies


Retracted: Hydroxycholorquine study pulled over suspect data.

Three of the four authors no longer vouch for the veracity of the primary data sources.

by Beth Mole - Jun 4, 2020 4:07pm EDT

https://arstechnica.com/science/2020...a-still-shady/


The Lancet medical journal on Thursday announced the retraction of a dubious study suggesting that the anti-malaria drugs chloroquine and hydroxychloroquine significantly increased the risk of death and heart-rhythm complications in hospitalized COVID-19 patients worldwide.

Three of the study’s four authors made the decision to retract the study after they were unable to independently verify the data used for their analysis. The data was provided by an obscure data analytics company, Surgisphere, which is run by the fourth author of the study, Sapan S Desai, who did not appear to agree to the retraction.
...In the meantime, the WHO announced Wednesday that it had resumed its trial of hydroxychloroquine after it reviewed the data and found no problems.
...


Update: 6/4/2020, 4:30pm ET: A second COVID-19 related study based on Surgisphere data has now been retracted. The study was published in The New England Journal of Medicine and looked at the effect of preexisting use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in COVID-19 patients. As in the case of the Lancet study, the authors reported that "Because all the authors were not granted access to the raw data and the raw data could not be made available to a third-party auditor, we are unable to validate the primary data sources underlying our article."